title: Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia.
abstract: Multicolor spectral karyotyping allows simultaneous visualization of all human chromosomes and screening for chromosomal rearrangements without a priori knowledge of any abnormalities involved. Based on this potentially increased sensitivity, we investigated, in a preliminary manner, whether spectral karyotyping could detect cytogenetic aberrations in karyotypically normal leukemia. The test population was comprised of 28 cryopreserved, cytogenetically normal acute myeloid leukemia (AML) samples from patients registered to a randomized trial for previously untreated AML (SWOG 9031). Two normal and 12 samples with known cytogenetic aberrations were used to validate and establish the diagnostic accuracy of the spectral karyotyping assay and instrumentation in a clinical setting. Enumeration and region-specific DNA fluorescence in situ hybridization (FISH) probes verified discrepant results. In the validation data set, spectral karyotyping refined complex karyotypic rearrangements in six cases and defined the chromosomal origin of a "jumping" homogeneously staining region; however, the technology was less sensitive in the detection of subtelomeric rearrangements and double minute chromosomes. In the test population, spectral karyotyping identified previously undetected cytogenetic aberrations in two cases (7%) of karyotypically normal AML: a cryptic 11q23 translocation in 20/20 cells and a minor monosomy 7 clone in 3/21 cells (FISH, 10.5%). Both of these abnormalities are considered to confer a poor prognosis when based on classical cytogenetic prognostic criteria. As an adjunct to classical cytogenetics and standard FISH analyses, the additive resolution of spectral karyotyping, in particular, with chromosome paints spiked with subtelomeric and/or locus-specific probes, may allow significant gains to be made in diagnostic accuracy and recognition of genotype/phenotype prognostic relationships, and in defining underlying biologic mechanisms in cancer. Genes Chromosomes Cancer 28:318-328, 2000.
authors.affiliation: Department of Cytogenetics, City of Hope National Medical Center, Duarte, California, USA.
authors.forename: F F
authors.initials: FF
authors.lastname: Zhang
authors.forename: J L
authors.initials: JL
authors.lastname: Murata-Collins
authors.forename: P
authors.initials: P
authors.lastname: Gaytan
authors.forename: S J
authors.initials: SJ
authors.lastname: Forman
authors.forename: K J
authors.initials: KJ
authors.lastname: Kopecky
authors.forename: C L
authors.initials: CL
authors.lastname: Willman
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: M L
authors.initials: ML
authors.lastname: Slovak
mesh_terms: D000208:Acute Disease; D002869:Chromosome Aberrations / Q000235:genetics*; D002871:Chromosome Banding / Q000592:standards; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping / Q000379:methods*; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D013194:Staining and Labeling / Q000379:methods* / Q000592:standards